+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Herpes Zoster Therapeutics Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • March 2022
  • Region: Global
  • TechNavio
  • ID: 5561272
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the herpes zoster therapeutics market and it is poised to grow by $4.51 bn during 2022-2026 progressing at a CAGR of 14.67% during the forecast period. The report on the herpes zoster therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased incidence of herpes zoster and rising geriatric population.

The herpes zoster therapeutics market analysis includes the product segment and geographic landscape.

The herpes zoster therapeutics market is segmented as below:


By Product


  • Vaccination
  • Drug therapy

By Geographical Landscape


  • North America
  • Europe
  • Asia
  • ROW

This study identifies favorable reimbursement policies for medications, including vaccines as one of the prime reasons driving the herpes zoster therapeutics market growth during the next few years.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The report on herpes zoster therapeutics market covers the following areas:
  • Herpes zoster therapeutics market sizing
  • Herpes zoster therapeutics market forecast
  • Herpes zoster therapeutics market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading herpes zoster therapeutics market vendors that include Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG. Also, the herpes zoster therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis: Pharmaceuticals
3. Market Sizing
3.1 Market segment analysis
Exhibit 11: Market segments
3.2 Market size 2021
3.3 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.4 Market outlook: Forecast for 2021 - 2026
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5 Market Segmentation by Product
5.1 Market segments
Exhibit 22: Product - Market share 2021-2026 (%)
5.2 Comparison by Product
Exhibit 23: Comparison by Product
5.3 Vaccination - Market size and forecast 2021-2026
Exhibit 24: Vaccination - Market size and forecast 2021-2026 ($ million)
Exhibit 25: Vaccination - Year-over-year growth 2021-2026 (%)
5.4 Drug therapy - Market size and forecast 2021-2026
Exhibit 26: Drug therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 27: Drug therapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Product
Exhibit 28: Market opportunity by Product
6. Customer landscape
6.1 Overview
  • The publisher's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 29: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 31: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 32: North America - Market size and forecast 2021-2026 ($ million)
Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 35: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 40: Key leading countries
7.8 Market opportunity By Geographical Landscape
Exhibit 41: Market opportunity By Geographical Landscape
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Increased incidence of herpes zoster
8.1.2 Rising geriatric population
8.1.3 Favorable reimbursement policies for medications, including vaccines
8.2 Market challenges
8.2.1 Weak pipeline for herpes zoster therapeutics
8.2.2 High generic influx of generics
8.2.3 Patient propensity toward substitutes
8.2.3 Patient propensity toward substitutes
Exhibit 42: Impact of drivers and challenges
8.3 Market trends
8.3.1 Emerging innovative vaccines for disease management
8.3.2 Vaccination programs and initiatives providing free vaccines
8.3.3 Expanding research
9. Vendor Landscape
9.1 Overview
Exhibit 43: Vendor landscape
The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
9.2 Landscape disruption
Exhibit 44: Landscape disruption
Exhibit 45: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 46: Vendors covered
10.2 Market positioning of vendors
Exhibit 47: Market positioning of vendors
10.3 Abbott Laboratories
Exhibit 48: Abbott Laboratories - Overview
Exhibit 49: Abbott Laboratories - Business segments
Exhibit 50: Abbott Laboratories - Key news
Exhibit 51: Abbott Laboratories - Key offerings
Exhibit 52: Abbott Laboratories - Segment focus
10.4 Akzo Nobel NV
Exhibit 53: Bausch Health Companies Inc. - Overview
Exhibit 54: Bausch Health Companies Inc. - Business segments
Exhibit 55: Bausch Health Companies Inc. - Key offerings
Exhibit 56: Bausch Health Companies Inc. - Segment focus
10.5 Zydus Lifesciences Ltd.
Exhibit 57: Zydus Lifesciences Ltd. - Overview
Exhibit 58: Zydus Lifesciences Ltd. - Business segments
Exhibit 59: Zydus Lifesciences Ltd. - Key offerings
Exhibit 60: Zydus Lifesciences Ltd. - Segment focus
10.6 Cipla Ltd.
Exhibit 61: Cipla Ltd. - Overview
Exhibit 62: Cipla Ltd. - Business segments
Exhibit 63: Cipla Ltd. - Key offerings
Exhibit 64: Cipla Ltd. - Segment focus
10.7 Eli Lilly and Co.
Exhibit 65: Eli Lilly and Co. - Overview
Exhibit 66: Eli Lilly and Co. - Business segments
Exhibit 67: Eli Lilly and Co. - Key offerings
Exhibit 68: Eli Lilly and Co. - Segment focus
10.8 Emcure Pharmaceuticals Ltd.
Exhibit 69: Emcure Pharmaceuticals Ltd. - Overview
Exhibit 70: Emcure Pharmaceuticals Ltd. - Product and service
Exhibit 71: Emcure Pharmaceuticals Ltd. - Key offerings
Exhibit 72: Emcure Pharmaceuticals Ltd. - Segment focus
10.9 GlaxoSmithKline Plc
Exhibit 73: GlaxoSmithKline Plc - Overview
Exhibit 74: GlaxoSmithKline Plc - Business segments
Exhibit 75: GlaxoSmithKline Plc - Key offerings
Exhibit 76: GlaxoSmithKline Plc - Segment focus
10.10 Maruho Co. Ltd.
Exhibit 77: Maruho Co. Ltd. - Overview
Exhibit 78: Maruho Co. Ltd. - Product and service
Exhibit 79: Maruho Co. Ltd. - Key offerings
10.11 Merck and Co. Inc.
Exhibit 80: Merck and Co. Inc. - Overview
Exhibit 81: Merck and Co. Inc. - Business segments
Exhibit 82: Merck and Co. Inc.- Key news
Exhibit 83: Merck and Co. Inc. - Key offerings
Exhibit 84: Merck and Co. Inc. - Segment focus
10.12 Novartis AG
Exhibit 85: Novartis AG - Overview
Exhibit 86: Novartis AG - Business segments
Exhibit 87: Novartis AG - Key offerings
Exhibit 88: Novartis AG - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and Caveats
11.2 Currency conversion rates for US$
Exhibit 89: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 90: Research Methodology
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Information sources
11.4 List of abbreviations
Exhibit 93: List of abbreviations
List of Exhibits
Exhibit 1: Key Finding 1
Exhibit 2: Key Finding 2
Exhibit 3: Key Finding 3
Exhibit 4: Key Finding 5
Exhibit 5: Key Finding 6
Exhibit 6: Key Finding 7
Exhibit 7: Key Finding 8
Exhibit 8: Parent market
Exhibit 9: Market characteristics
Exhibit 10: Offerings of vendors included in the market definition
Exhibit 11: Market segments
Exhibit 12: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 13: Global market: Year-over-year growth 2021 - 2026 (%)
Exhibit 14: Five forces analysis 2021 & 2026
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition - Five forces 2021
Exhibit 21: Product - Market share 2021-2026 (%)
Exhibit 22: Comparison by Product
Exhibit 23: Vaccination - Market size and forecast 2021-2026 ($ million)
Exhibit 24: Vaccination - Year-over-year growth 2021-2026 (%)
Exhibit 25: Drug therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 26: Drug therapy - Year-over-year growth 2021-2026 (%)
Exhibit 27: Market opportunity by Product
Exhibit 28: Customer landscape
Exhibit 29: Market share By Geographical Landscape 2021-2026 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2021-2026 ($ million)
Exhibit 32: North America - Year-over-year growth 2021-2026 (%)
Exhibit 33: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Europe - Year-over-year growth 2021-2026 (%)
Exhibit 35: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 36: Asia - Year-over-year growth 2021-2026 (%)
Exhibit 37: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 38: ROW - Year-over-year growth 2021-2026 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity By Geographical Landscape ($ million)
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Industry risks
Exhibit 45: Vendors covered
Exhibit 46: Market positioning of vendors
Exhibit 47: Abbott Laboratories - Overview
Exhibit 48: Abbott Laboratories - Business segments
Exhibit 49: Abbott Laboratories - Key offerings
Exhibit 50: Abbott Laboratories - Key customers
Exhibit 51: Abbott Laboratories - Segment focus
Exhibit 52: Bausch Health Companies Inc. - Overview
Exhibit 53: Bausch Health Companies Inc. - Business segments
Exhibit 54: Bausch Health Companies Inc. - Key offerings
Exhibit 55: Bausch Health Companies Inc. - Key customers
Exhibit 56: Bausch Health Companies Inc. - Segment focus
Exhibit 57: Zydus Lifesciences Ltd. - Overview
Exhibit 58: Zydus Lifesciences Ltd. - Business segments
Exhibit 59: Zydus Lifesciences Ltd. - Key offerings
Exhibit 60: Zydus Lifesciences Ltd. - Key customers
Exhibit 61: Zydus Lifesciences Ltd. - Segment focus
Exhibit 62: Cipla Ltd. - Overview
Exhibit 63: Cipla Ltd. - Business segments
Exhibit 64: Cipla Ltd. - Key offerings
Exhibit 65: Cipla Ltd. - Key customers
Exhibit 66: Cipla Ltd. - Segment focus
Exhibit 67: Eli Lilly and Co. - Overview
Exhibit 68: Eli Lilly and Co. - Business segments
Exhibit 69: Eli Lilly and Co. - Key offerings
Exhibit 70: Eli Lilly and Co. - Key customers
Exhibit 71: Eli Lilly and Co. - Segment focus
Exhibit 72: Emcure Pharmaceuticals Ltd. - Overview
Exhibit 73: Emcure Pharmaceuticals Ltd. - Product and service
Exhibit 74: Emcure Pharmaceuticals Ltd. - Key offerings
Exhibit 75: Emcure Pharmaceuticals Ltd. - Key customers
Exhibit 76: Emcure Pharmaceuticals Ltd. - Segment focus
Exhibit 77: GlaxoSmithKline Plc - Overview
Exhibit 78: GlaxoSmithKline Plc - Business segments
Exhibit 79: GlaxoSmithKline Plc - Key offerings
Exhibit 80: GlaxoSmithKline Plc - Key customers
Exhibit 81: GlaxoSmithKline Plc - Segment focus
Exhibit 82: Maruho Co. Ltd. - Overview
Exhibit 83: Maruho Co. Ltd. - Product and service
Exhibit 84: Maruho Co. Ltd. - Key offerings
Exhibit 85: Maruho Co. Ltd. - Key customers
Exhibit 86: Maruho Co. Ltd. - Segment focus
Exhibit 87: Merck and Co. Inc. - Overview
Exhibit 88: Merck and Co. Inc. - Business segments
Exhibit 89: Merck and Co. Inc. - Key offerings
Exhibit 90: Merck and Co. Inc. - Key customers
Exhibit 91: Merck and Co. Inc. - Segment focus
Exhibit 92: Novartis AG - Overview
Exhibit 93: Novartis AG - Business segments
Exhibit 94: Novartis AG - Key offerings
Exhibit 95: Novartis AG - Key customers
Exhibit 96: Novartis AG - Segment focus
Exhibit 97: Currency conversion rates for US$
Exhibit 98: Research Methodology
Exhibit 99: Validation techniques employed for market sizing
Exhibit 100: Information sources
Exhibit 101: List of abbreviations

Executive Summary

The publisher announces the Publication of its Research Report - Global Herpes Zoster Therapeutics Market 2022-2026

The publisher recognizes the following companies as the key players in the global herpes zoster therapeutics market: Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG.

Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is favorable reimbursement policies for medications, including vaccines.'

According to the report, one of the major drivers for this market is the increased incidence of herpes zoster.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Bausch Health Companies Inc.
  • Zydus Lifesciences Ltd.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • Emcure Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck and Co. Inc.
  • Novartis AG